Ureteral Neoplasms

"Ureteral Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Cancer or tumors of the URETER which may cause obstruction leading to hydroureter, HYDRONEPHROSIS, and PYELONEPHRITIS. HEMATURIA is a common symptom.

Descriptor ID	D014516
MeSH Number(s)	C04.588.945.947.940 C12.758.820.875 C12.777.725.676 C13.351.937.820.875 C13.351.968.725.676
Concept/Terms	Ureteral Neoplasms Ureteral Neoplasms Neoplasm, Ureteral Ureteral Neoplasm Neoplasms, Ureteral Ureter Neoplasms Ureter Neoplasm Neoplasms of Ureter Cancer of Ureter Cancer of Ureter Ureter Cancers Ureter, Cancer Of Ureter Cancer Ureteral Cancer Cancer, Ureteral Cancers, Ureteral Ureteral Cancers Cancer of the Ureter

Below are MeSH descriptors whose meaning is more general than "Ureteral Neoplasms".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Urogenital Neoplasms [C04.588.945]
Urologic Neoplasms [C04.588.945.947]
Ureteral Neoplasms [C04.588.945.947.940]
Male Urogenital Diseases [C12]
Urogenital Neoplasms [C12.758]
Urologic Neoplasms [C12.758.820]
Ureteral Neoplasms [C12.758.820.875]
Urologic Diseases [C12.777]
Ureteral Diseases [C12.777.725]
Ureteral Neoplasms [C12.777.725.676]
Female Urogenital Diseases and Pregnancy Complications [C13]
Female Urogenital Diseases [C13.351]
Urogenital Neoplasms [C13.351.937]
Urologic Neoplasms [C13.351.937.820]
Ureteral Neoplasms [C13.351.937.820.875]
Urologic Diseases [C13.351.968]
Ureteral Diseases [C13.351.968.725]
Ureteral Neoplasms [C13.351.968.725.676]

Below are MeSH descriptors whose meaning is related to "Ureteral Neoplasms".

Below are MeSH descriptors whose meaning is more specific than "Ureteral Neoplasms".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Ureteral Neoplasms" by people in this website by year, and whether "Ureteral Neoplasms" was a major or minor topic of these publications.

Bar chart showing 31 publications over 16 distinct years, with a maximum of 5 publications in 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	3	0	3
1998	1	0	1
1999	1	0	1
2004	0	1	1
2005	1	0	1
2008	3	1	4
2010	1	0	1
2012	1	0	1
2013	2	0	2
2014	2	0	2
2017	1	0	1
2018	1	0	1
2019	2	0	2
2020	3	0	3
2023	2	0	2
2024	3	2	5

Below are the most recent publications written about "Ureteral Neoplasms" by people in Profiles.

Pierorazio PM, Kleinmann N, Shabsigh A, Hu B, Raman JD, Kaimakliotis H, Sankin A, Singla N, Meads A, Burger B, Raju S, Louie MJ, Chamie K, Weizer A, Schoenberg M. Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel. J Urol. 2025 03; 213(3):313-322.

View in: PubMed
Lasmanovich R, Shvero A, Kleinmann N. Upper tract urothelial carcinoma: conservative management - intraluminal adjuvant therapy, and surveillance. Curr Opin Urol. 2025 01 01; 35(1):68-74.

View in: PubMed
Vlachou E, Hoffman-Censits J, Singla N. The biologic landscape and therapeutic implications of upper tract urothelial cancer. Curr Opin Urol. 2025 01 01; 35(1):89-95.

View in: PubMed
Parmar K, Hanson M, Mahrous AS, Keeley FX, Timoney AG, Albuheissi S, Rai BP, Philip J. Focused UTUC pathways with a risk-stratified approach to diagnostic ureteroscopy: is it the need of the hour? A retrospective cohort analysis. World J Urol. 2024 Feb 10; 42(1):76.

View in: PubMed
Fletcher SA, Pallauf M, Watts EK, Lombardo KA, Campbell JA, Rezaee ME, Roupr?t M, Boorjian SA, Potretzke AM, Roshandel MR, Ploussard G, Djaladat H, Ghoreifi A, Mari A, Campi R, Khene ZE, Raman JD, Kikuchi E, Rink M, Abdollah F, Boormans JL, Fujita K, D'Andrea D, Soria F, Breda A, Hoffman-Censits J, McConkey DJ, Shariat SF, Pradere B, Singla N. Oncologic Outcomes in Patients with Residual Upper Tract Urothelial Carcinoma Following Neoadjuvant Chemotherapy. Eur Urol Oncol. 2024 Oct; 7(5):1061-1068.

View in: PubMed
Syd?n F, Baard J, Bultitude M, Keeley FX, Roupr?t M, Thomas K, Axelsson TA, Jaremko G, Jung H, Malm C, Proietti S, Osther PJS, Brehmer M. Consultation on UTUC II Stockholm 2022: diagnostics, prognostication, and follow-up-where are we today? World J Urol. 2023 Dec; 41(12):3395-3403.

View in: PubMed
Coleman JA, Clark PE, Bixler BR, Buckley DI, Chang SS, Chou R, Hoffman-Censits J, Kulkarni GS, Matin SF, Pierorazio PM, Potretzke AM, Psutka SP, Raman JD, Smith AB, Smith L. Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline. J Urol. 2023 06; 209(6):1071-1081.

View in: PubMed
Cheaib JG, Claus LE, Patel HD, Kates MR, Matoso A, Hahn NM, Bivalacqua TJ, Hoffman-Censits JH, Pierorazio PM. Site of metastatic recurrence impacts prognosis in patients with high-grade upper tract urothelial carcinoma. Urol Oncol. 2021 01; 39(1):74.e9-74.e16.

View in: PubMed
Scotland KB, Hubbard L, Cason D, Banks J, Leong JY, Healy K, Leiby B, Hubosky SG, Bagley DH. Long term outcomes of ureteroscopic management of upper tract urothelial carcinoma. Urol Oncol. 2020 11; 38(11):850.e17-850.e26.

View in: PubMed
Haifler M, Shvero A, Zilberman D, Ramon J, Winkler H, Margel D, Kleinmann N. Tandem Ureteral Stents for Malignant Ureteral Obstruction. J Endourol. 2020 02; 34(2):222-226.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement